Published in PLoS One on May 08, 2012
Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol (2012) 1.21
Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results. Sci Rep (2015) 0.87
Numerical Modeling of Interstitial Fluid Flow Coupled with Blood Flow through a Remodeled Solid Tumor Microvascular Network. PLoS One (2013) 0.87
Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities. Biotechnol Adv (2013) 0.80
The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancer. PLoS One (2013) 0.78
Selection strategies for anticancer antibody discovery: searching off the beaten path. Trends Biotechnol (2015) 0.76
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. Mol Cancer Ther (2016) 0.76
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET. Nucl Med Mol Imaging (2016) 0.76
Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy. PLoS One (2015) 0.75
Radioimmunoimaging of liver metastases with PET using a 64Cu-labeled CEA antibody in transgenic mice. PLoS One (2014) 0.75
Posttranslational mechanisms regulate the mammalian circadian clock. Cell (2001) 7.93
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol (2007) 7.33
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer (2004) 5.99
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet (1994) 3.24
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res (2004) 2.78
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer (2006) 2.45
Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye DiI. Nat Protoc (2008) 2.29
Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet (1982) 2.25
Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res (1987) 2.22
Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng (2011) 2.17
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet (2000) 1.94
Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res (1991) 1.73
Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res (1977) 1.71
The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol (2003) 1.68
Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res (2004) 1.46
Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res (1988) 1.29
Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res (2004) 1.27
Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer (1997) 1.25
Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol (2006) 1.23
Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer (2006) 1.17
Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One (2009) 1.05
Detection limits of intraoperative near infrared imaging for tumor resection. J Surg Oncol (2010) 1.01
Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Oncogene (2011) 0.89
Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro. Lung Cancer (2011) 0.87
Investigations on the usefulness of CEACAMs as potential imaging targets for molecular imaging purposes. PLoS One (2011) 0.84
Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model. J Immunol (2007) 0.81
Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody. Anticancer Res (2007) 0.79
Biosynthesis and glycosylation of the carcinoma-associated antigen recognized by monoclonal antibody KS1/4. Cancer Res (1990) 0.77
Radioimmunodetection of human small cell lung carcinoma xenografts in the nude rat using 111in-labelled monoclonal antibody MOC-31. Eur J Cancer (1993) 0.77
Brown adipose tissue activity controls triglyceride clearance. Nat Med (2011) 6.76
SPECT/CT. J Nucl Med (2008) 2.34
Myeloperoxidase attracts neutrophils by physical forces. Blood (2010) 1.84
The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci U S A (2009) 1.77
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol (2002) 1.75
Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev (2002) 1.58
CEACAM1+ myeloid cells control angiogenesis in inflammation. Blood (2009) 1.57
Size and surface effects on the MRI relaxivity of manganese ferrite nanoparticle contrast agents. Nano Lett (2007) 1.56
A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. PLoS One (2010) 1.54
Real-time magnetic resonance imaging and quantification of lipoprotein metabolism in vivo using nanocrystals. Nat Nanotechnol (2009) 1.47
Temporary esophageal stenting allows healing of esophageal perforations following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol (2006) 1.44
Diagnostic accuracy of state-of-the-art MDCT scanners without gantry tilt in patients with oral and oropharyngeal cancer. Eur J Radiol (2011) 1.44
Tetrastarch sustains pulmonary microvascular perfusion and gas exchange during systemic inflammation. Crit Care Med (2012) 1.40
Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer (2002) 1.38
Peroxisome elongation and constriction but not fission can occur independently of dynamin-like protein 1. J Cell Sci (2004) 1.32
Cartilage destruction in granulomatosis with polyangiitis (Wegener's granulomatosis) is mediated by human fibroblasts after transplantation into immunodeficient mice. Am J Pathol (2012) 1.29
PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem (2011) 1.28
Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer (2011) 1.27
PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem (2006) 1.26
Extracellular NAD and ATP: Partners in immune cell modulation. Purinergic Signal (2007) 1.26
Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res (2009) 1.26
Assessment of resident surgical skills: is testing feasible? Am J Obstet Gynecol (2005) 1.25
Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med (2004) 1.22
CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol (2002) 1.21
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol (2013) 1.19
Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer (2005) 1.19
Macrophage internal HIV-1 is protected from neutralizing antibodies. J Virol (2011) 1.19
Inhibition of hyaluronan export from human fibroblasts by inhibitors of multidrug resistance transporters. Biochem Pharmacol (2004) 1.17
Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer (2007) 1.17
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci (2005) 1.14
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer (2012) 1.14
PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med (2011) 1.13
Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol (2003) 1.13
A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res (2003) 1.13
Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer (2008) 1.13
Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals (2007) 1.12
Assessing quality obstetrical care: development of standardized measures. Jt Comm J Qual Patient Saf (2006) 1.12
Viral mediated redirection of NEMO/IKKγ to autophagosomes curtails the inflammatory cascade. PLoS Pathog (2012) 1.11
Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest (2013) 1.11
Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer (2013) 1.09
Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit Rev Oncol Hematol (2007) 1.08
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog (2013) 1.08
Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem (2013) 1.07
Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol (2011) 1.07
Antisense therapy for cancer--the time of truth. Lancet Oncol (2002) 1.06
Rat liver peroxisomes after fibrate treatment. A survey using quantitative mass spectrometry. J Biol Chem (2007) 1.06
Oxidative stress precedes peak systemic inflammatory response in pediatric patients undergoing cardiopulmonary bypass operation. Free Radic Biol Med (2005) 1.05
A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis (2012) 1.05
bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity. J Biol Chem (2003) 1.04
Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. Clin Cancer Res (2004) 1.04
Initial outcomes from a 4-week follow-up study of the Text4baby program in the military women's population: randomized controlled trial. J Med Internet Res (2014) 1.03
Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int (2006) 1.02
Ceramide kinase contributes to proliferation but not to prostaglandin E2 formation in renal mesangial cells and fibroblasts. Cell Physiol Biochem (2014) 1.02
Evaluating driving performance of cognitively impaired and healthy older adults: a pilot study comparing on-road testing and driving simulation. J Am Geriatr Soc (2002) 1.02
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res (2009) 1.02
Pex11pbeta-mediated growth and division of mammalian peroxisomes follows a maturation pathway. J Cell Sci (2010) 1.01
The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death. Br J Pharmacol (2014) 1.01
Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic Biol Med (2009) 1.01
Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med (2008) 1.01
Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem (2007) 1.01
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int J Cancer (2003) 1.00
Expression and prognostic value of L1-CAM in breast cancer. Oncol Rep (2009) 1.00
Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo. J Clin Invest (2006) 0.99
Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer (2010) 0.99
EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol Cancer Ther (2009) 0.99
Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol (2011) 0.99
A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther (2005) 0.98
Hitchhiking of Cu/Zn superoxide dismutase to peroxisomes--evidence for a natural piggyback import mechanism in mammals. Traffic (2009) 0.98
Replication, gene expression and particle production by a consensus Merkel Cell Polyomavirus (MCPyV) genome. PLoS One (2011) 0.98
Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. J Med Chem (2011) 0.98
Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. Int J Med Sci (2008) 0.98
Human prostate cancer in a clinically relevant xenograft mouse model: identification of β(1,6)-branched oligosaccharides as a marker of tumor progression. Clin Cancer Res (2012) 0.97
DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J Mol Biol (2011) 0.97
Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther (2007) 0.97
p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia (2006) 0.97
Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer (2010) 0.97
A new curriculum for hysteroscopy training as demonstrated by an objective structured assessment of technical skills (OSATS). Am J Obstet Gynecol (2005) 0.97
High-throughput identification of reference genes for research and clinical RT-qPCR analysis of breast cancer samples. J Clin Bioinforma (2013) 0.96
Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Mol Cancer (2013) 0.96
Electroporation of primary neural cultures: a simple method for directed gene transfer in vitro. Histochem Cell Biol (2002) 0.95
Does liver biopsy overestimate liver iron concentration? Blood (2006) 0.95
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med (2016) 0.94
Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology (2005) 0.94
Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opin Drug Deliv (2013) 0.94
Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells. J Hepatol (2012) 0.93
A simple and widely applicable method to 59Fe-radiolabel monodisperse superparamagnetic iron oxide nanoparticles for in vivo quantification studies. ACS Nano (2012) 0.93
An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to fas and TNFalpha mediated apoptosis. Prostate (2004) 0.93
Pseudomonas aeruginosa lectins I and II and their interaction with human airway cilia. J Laryngol Otol (2005) 0.92
Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res Treat (2002) 0.92
John M. Eisenberg Patient Safety and Quality Awards. Impact of CRM-based training on obstetric outcomes and clinicians' patient safety attitudes. Jt Comm J Qual Patient Saf (2007) 0.92